Enliven Therapeutics grants Ball 23,394 options

The director's options vest monthly beginning November 14, 2026, subject to her continuing as an outside director through each vesting date.

Rhea-AI Filing Summary

Kristine M. Ball, a director of Enliven Therapeutics, Inc. (ELVN), received a grant of 23,394 stock options on October 14, 2026, at an exercise price of $39.28 per share. Her resulting option position was 23,394. One thirty-sixth of the shares subject to the option vests on November 14, 2026, and each month thereafter, subject to her continuing as an outside director through each vesting date. The options expire October 14, 2036.

Insider Trade Summary

Grant/Award: 23,394 shares

Grant/Award 1 txn

Insider BALL KRISTINE M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	23,394	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 23,394 contracts (Direct)

Footnotes (1)

1. F1. 1/36th of the shares subject to the option will vest on November 14, 2026 and each month thereafter, subject to the Reporting Person continuing as an outside director through each such date.

Key Figures

Stock options granted: 23,394 options Exercise price: $39.28 per share Options following grant: 23,394 options +2 more

5 metrics

Stock options granted 23,394 options Grant dated October 14, 2026

Exercise price $39.28 per share Granted stock options

Options following grant 23,394 options Kristine M. Ball's resulting option position

Vesting installment 1/36th of the shares subject to the option Begins November 14, 2026, and continues monthly, subject to continued outside-director service through each vesting date

Option expiration October 14, 2036 Stock options granted October 14, 2026

Key Terms

Stock Option (right to buy), vest, outside director, exercise price

4 terms

Stock Option (right to buy) financial

"Stock Option (right to buy)"

vest financial

"the shares subject to the option will vest"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

outside director financial

"continuing as an outside director through each such date"

exercise price financial

"exercise price of $39.28 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did ELVN director Kristine M. Ball receive?

Kristine M. Ball received 23,394 stock options on October 14, 2026, at an exercise price of $39.28 per share.

When do Kristine M. Ball's ELVN options expire?

The options expire on October 14, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/16/2026 - 04:43 PM EDT Accepted by SEC EDGAR 10/16/2026 - 04:42 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BALL KRISTINE M

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

205 PARK ROAD

(Street)

BURLINGAME CALIFORNIA 94010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$39.28	10/14/2026		A		23,394		(1)	10/14/2036	Common Stock	23,394	$0	23,394	D

Explanation of Responses:

1. 1/36th of the shares subject to the option will vest on November 14, 2026 and each month thereafter, subject to the Reporting Person continuing as an outside director through each such date.

	/s/ Ben Hohl, by power of attorney	10/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)